Tego Science, Inc. Reports 87% Increase in Third-Quarter Revenue Following Subsidiary Acquisition… Operating Loss Down 40%
Consolidated Revenue of 3 Billion Won, Operating Loss of 600 Million Won… Quarterly Profitability Improves
Standalone revenue rose only 4.9%… Cumulative revenue fell 2.4%
TPX-115 Phase 2b Clinical Trial Follow-up Completed…Top-line Results to Be Announced in January Next Year
[Edaily Reporter KIM SAE-MI ] Tego Science, Inc.(191420)reported an 87% year-over-year increase in consolidated revenue for the third quarter of this year, driven by the consolidation of a subsidiary. Thanks to the revenue growth, the operating loss also decreased by 40%.
Tego Science, Inc. logo (Photo courtesy of Tego Science, Inc.) Tego Science, Inc. announced on the 16th that its consolidated operating loss for the third quarter of this year was 600 million won, a 40.1% decrease from the 1 billion won recorded in the same period last year. During the same period, revenue rose 86.7% to 3 billion won, while the net loss fell 55.6% to 400 million won from 1 billion won in the prior-year period.
The company explained that revenue growth was driven by the inclusion of results from P&P Pharm, a pharmaceutical wholesaler and retailer newly acquired this year, as well as expanded sales of the autologous cell therapy product “Caloderm.”
However, based on standalone financial statements—excluding the results of subsidiaries—the revenue growth rate was limited to around 5%. Standalone revenue for the third quarter of this year was 1.6 billion won, a 4.9% increase compared to the same period last year. The operating loss was 700 million won, a 23.9% reduction from the 900 million won loss in the same period last year.
Cumulative consolidated revenue for the first three quarters of this year reached 6.2 billion won, a 36.2% increase compared to the same period last year, while the operating loss widened by 55.7% year-over-year to 3.6 billion won. In contrast, cumulative standalone revenue decreased by 2.4% year-over-year to 4.1 billion won, and the operating loss increased by 63% year-over-year to 3.7 billion won.
Tego Science, Inc. completed the last patient’s long-term follow-up (LPO) on the 9th for the Phase 2b clinical trial of “TPX-115,” a cell therapy for partial rotator cuff tears. Following database lock (DBL) and statistical analysis, the company plans to announce topline results in January of next year.
Following a review by an independent expert panel, the company finalized the number of subjects for the Phase 3 clinical trial and submitted an application to the Ministry of Food and Drug Safety (MFDS) to amend the clinical trial protocol. It plans to commence the Phase 3 trial as soon as approval is granted. The company is currently in the process of applying for approval of the Phase 2/3 clinical trial protocol for “TPX-121,” a cell therapy for wrinkle reduction.
Jeon Se-hwa, CEO of Tego Science, Inc., stated, “We achieved meaningful revenue growth driven by the combined effects of the subsidiary’s integration and expanded sales of Caloderm.” He added, “While maintaining this growth momentum in the fourth quarter, we will ensure the successful completion of the Phase 2 trial for TPX-115 and proceed with the Phase 3 trial without delay, and we will also swiftly advance the Phase 2/3 trial for TPX-121.”
LGELECTRONICS is partnering with the Korea Robot Industry Promotion Agency to enhance the safety and quality competitiveness of humanoid robots. Ahead of the unveiling of a bipedal robot in the first …
DONGWOON ANATECH CO.,LTD.(094170), which has grown primarily by manufacturing semiconductors for smartphone cameras, is expanding its business into the automotive and robotics markets. Following the a…
SKTelecom(017670)has partnered with HYOSUNG HEAVY INDUSTRIES(298040)to secure key power infrastructure for the construction of a gigawatt (GW)-class, ultra-large artificial intelligence (AI) data cent…